CRISPR Therapeutics AG

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines for serious diseases through its proprietary CRISPR/Cas9 gene-editing platform. The company’s current portfolio spans hematology, oncology, autoimmune disorders, cardiovascular disease, regenerative medicine, and type 1 diabetes. Its leading commercial therapy, CASGEVY, is an ex vivo gene-edited cell therapy designed for eligible patients with transfusion-dependent beta thalassemia and severe sickle cell disease. CRISPR Therapeutics AG also develops allogeneic and autologous CAR T-cell therapies for cancer and autoimmune indications, including programs directed at CD19 and CD70. Its in vivo gene-editing programs target biological pathways associated with cardiovascular conditions, while stem cell-derived therapies address insulin-producing cell replacement for type 1 diabetes. Headquartered in Zug, Switzerland, the company operates at the intersection of molecular biology, cell therapy, and precision medicine, contributing to the development of treatments that modify disease-related genetic or cellular mechanisms rather than relying solely on conventional pharmaceuticals.